Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MUHDfZRwfG:6aXRCpIF{e2G7 M2rnS|Q5KGh? MmjCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUTlMVA3KM7:TT6= MYWyNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) MmXxVJJwdGmoZYLheIlwdiCjc4PhfS=> M4T1fGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> MlnHNVE2QTF3MEW=
human LoVo cells NWTiWXZzWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2XCSFQ5KHSxIEeyJIg> MlHnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> MXmyNlE5Ojl{OR?=
P19 cells NYq4SZJXTnWwY4Tpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDy[YNmeHSxcjDpckBROTliY3XscJMtKEmFNUC9NE4xODJizszNMi=> MlnNNVU4PzF2MUm=
human BJ cells MoDSR5l1d3SxeHnjxsBie3OjeR?= M{DnUVczKGh? M1XMPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTBwMECyJO69VS5? NUXJOpJkOjJ7MkGwPFE>
human HT-29 cells M1\NSGZ2dmO2aX;uJIF{e2G7 NUj0fGh5OiCq MlzkSYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 MWWyNVQzQDN5NR?=
human A549 cells MYrDfZRwfG:6aXRCpIF{e2G7 NUHTZVV5PzJiaB?= NIG5R4lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJI1mfGixZB?= MXuxPFQ5PDd5NR?=
human HT-29 cells NWnjWWRJTnWwY4Tpc44h[XO|YYm= Ml\GTY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O M{TCfVIyPTF|Mkmz
human HT-29 cells NIXxOolHfW6ldHnvckBie3OjeR?= NI\5cnczKGh? NIq1VlZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> M17xSVIyQTd|MUCx
Sf9 cells NY\VPFE1TnWwY4Tpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJHN6cyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUOgcm0v NVnmeFNTOTh6MkO3PFQ>
human HUVEC M125TXBzd2yrZnXyZZRqd25iYYPzZZk> M4LyOFQ5KHSxIEeyJIg> MmLkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 M3ezcFIzOTh{OUK5
P19 cells MoLWSpVv[3Srb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy|LDDJR|UxRTRibl2u MWKxOVc4OTRzOR?=
Sf9 cells NIrGUldHfW6ldHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgcYlvKGK7IFXMTXNCKGmwIIDy[ZNmdmOnIH;mJFEhfW2xbD;MJGFVWA>? MYGxO|MyPTh3Mx?=
Sf21 cells NX7jXGloTnWwY4Tpc44h[XO|YYm= NU\uZ3diUW6qaXLpeIlwdiCxZjDKRWs{KGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzMEBKSzVyPU[gcm0v NF;SUmYyPzB6OEC1PS=>
human colon carcinoma cell line HCT116 NV\UeGxrTnWwY4Tpc44h[XO|YYm= M{\xcGNwdmOnboTyZZRqd25icnXxeYlz\WRiZn;yJIdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKGyrbnWgTGNVOTF4LDDJR|UxRTZibl2u MVWxOVU{PzN2NR?=
human ST486 cells MX3Qdo9tcW[ncnH0bY9vKGG|c3H5 M1zVTFQ5KHSxIEeyJIg> M3\uemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2S0PFYh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF04KG6PLh?= NI[z[XIzOjF6MkmyPS=>
human MDA-MB-231 cells NGHieXREgXSxdH;4bYPDqGG|c3H5 NFvuW2M4OiCq NXnZT5RJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2RuIFfJOVA:Py5zIH7NMi=> M1;aT|E5PDh2N{e1
P19 cells MlriSpVv[3Srb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u MkTqNVU4PzF2MUm=
human DLD1 cells NXzRSHJlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHr1bVI1QC15MjDo NYfwOmpbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEUGQyKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QSCwTT6= NWXNbHZROjJzOEK5Nlk>
insect cells NHvKNoxHfW6ldHnvckBie3OjeR?= MlnhTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSaX2xJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkhUFSURjygTWM2OD1zMDDuUU4> M2fRWFE6OTd7MEe2
V79 MZ cells M1\wTmZ2dmO2aX;uJIF{e2G7 M37v[GlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> Mnj1NlQ1OjJ3MUm=
P19 cells MXTGeY5kfGmxbjDhd5NigQ>? Mn[4TY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKGmwIGCxPUBk\WyuczygTWM2OD1zNDDuUU4> MYGxOVc4OTRzOR?=
Sf9 cells NWHTXFBpTnWwY4Tpc44h[XO|YYm= MYCyNEBucW6| NHn4e41KdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFIxKG2rboOgZpkhTUyLU1GgbY4heHKnc3XuZ4Uhd2ZiMTD1cY9tN0xiQWTQMEBKSzVyPUG1JI5ONg>? MV[xO|MyPTh3Mx?=
human PBMC MX7GeY5kfGmxbjDhd5NigQ>? NEnzWmczPCCq NYmx[W5bW3WycILld5Nqd25ib3[gTWwzKHC{b3T1Z5Rqd25iaX6gbJVu[W5iUFLNR{Bi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVA:OTZibl2u MorQNVg2QDVyNE[=
human A549 cells MmL1R5l1d3SxeHnjxsBie3OjeR?= NWrBN2dHPDhiaB?= M4e1NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w MlznNlU5OjV7M{S=
human CEM cells MnnmR5l1d3SxeHnjxsBie3OjeR?= NELz[II4OiCq Ml\PR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTJ|IH7NMi=> MYeyNlkzOTB6MR?=
human HeLa cells MX\DfZRwfG:6aXRCpIF{e2G7 NUmx[4x5PDhiaB?= MkL0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JI5ONg>? M2O5NFI2QDJ3OUO0
human PC3 cells MkHVR5l1d3SxeHnjxsBie3OjeR?= Mnr2OFghcA>? MkXlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? MY[yOVgzPTl|NB?=
human SF268 cells MoHER5l1d3SxeHnjxsBie3OjeR?= NGPBfWY1QCCq NUS2RVg4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= NYTXW2VkOjF3MUOyPVQ>
human MCF7 cells NWezc|R6S3m2b4TvfIlkyqCjc4PhfS=> MlrQOFghcA>? NXi5SI0xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= NVfDZmR3OjF|OEixPVE>
HEK293 cells Mni2R5l1d3SxeHnjxsBie3OjeR?= MYG3NkBp M4\0XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{R3zvJIF{e2G7LDDJR|UxRTV4IH7NMi=> NXjEZnJyOjR5NkOyOlI>
HUE cells MXvGeY5kfGmxbjDhd5NigQ>? MXO5NEBucW6| NVjQc|JMUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w NXLhTpllOjBzN{CxOlM>
human A431 cells NVOyXVQxS3m2b4TvfIlkyqCjc4PhfS=> MWOyOEAhcA>? M{eyUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= MWmyNlU1OTB3MR?=
human Jurkat cells NFPHZlNRem:uaX\ldoF1cW:wIHHzd4F6 NFLMdlBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGpCUzNiZYjwdoV{e2mwZzDJUFIue3SrbYXsZZRm\CCqdX3hckBLfXKtYYSgZ4VtdHNuIFnDOVA:PzFibl2u NWPEZ3N5OTl2MkeyNFM>
HEK293 cells NFPWcZFHfW6ldHnvckBie3OjeR?= NYfiWmpWUW6qaXLpeIlwdiCxZjDJUE05KHKnbHXhd4Uh[nliSFXLNlk{KGOnbHzzJIV5eHKnc4PpcochWEuFLXLleIEzNCCLQ{WwQVc4KG6PLh?= NHfJN|EyPTd5MUSxPS=>
human KE-97 cells M13UPWN6fG:2b4jpZ:Kh[XO|YYm= NHPZNJc4OiCq MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= MkLFNlQ{Ojh{OEO=
human CHOK1 cells M4TVd2N6fG:2b4jpZ:Kh[XO|YYm= MVe0PEBp MnjLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> MW[yNVUyOzJ7NB?=
mouse NIH/3T3 cells M{X3O2N6fG:2b4jpZ:Kh[XO|YYm= NH7BdYw6PiCq NYf5TGloS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v Mmj4NlQ{PjF3MkG=
human A2780 cells MXXDfZRwfG:6aXRCpIF{e2G7 MWC5OkBp NFvBdnlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NXTlbY1XOjR|NkG1NlE>
human 8505C cells M2TsNmN6fG:2b4jpZ:Kh[XO|YYm= NILT[XA6PiCq NUPpW|N3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hQDVyNVOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> NUnlWFNGOjR|NkG1NlE>
human 518A2 cells Ml3QR5l1d3SxeHnjxsBie3OjeR?= NXPq[mtjQTZiaB?= NGLmXnlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> M{PaVVI1OzZzNUKx
human HuH7 cells Mof2R5l1d3SxeHnjxsBie3OjeR?= MoflO|IhcA>? M{jWPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOyEQvF2u M3HnOFI1OzJ6Mkiz
FL5.12-Akt1 cells MWrQdo9tcW[ncnH0bY9vKGG|c3H5 M{PRU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> M2XWWVE3PDB|NkK2
human MiaPaCa-2 cells M3H4S3Bzd2yrZnXyZZRqd25iYYPzZZk> NGTKeHdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3pZXBiS2FvMjDj[YxteyxiSVO1NF0xNjN5IN88UU4> MVKxOlQyOzd6MB?=
human BGC823 cells M2eycmN6fG:2b4jpZ:Kh[XO|YYm= M{TGWVczKGh? NU\iUYlOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? NGLBZXUzPDN{OEK4Ny=>
human MCF7 cells M{L0[WN6fG:2b4jpZ:Kh[XO|YYm= MmT5PVYhcA>? NF[ybWdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TT6= NXXl[GRuOjR|NkG1NlE>
human A549 cells M{fYOWN6fG:2b4jpZ:Kh[XO|YYm= M17FdFk3KGh? NWD0b5o4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u M4HC[lI1OzZzNUKx
HEK293 cells MV;DfZRwfG:6aXRCpIF{e2G7 MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNuIFXDOVA:OiEQvF2u M17h[VI2OzF4M{G3
human Raji cells  MYnDfZRwfG:6aXRCpIF{e2G7 NFTWRoREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= MVeyOVMyPjNzNx?=
human HepG2 cells NHXQNJpEgXSxdH;4bYPDqGG|c3H5 MoC0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEWFNUC9NkDPxE1w MmHpNlU{OTZ|MUe=
human BJ cells MnXWR5l1d3SxeHnjxsBie3OjeR?= MnnvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v MXGyOVMyPjNzNx?=
human U937 cells NHXnOI1EgXSxdH;4bYPDqGG|c3H5 MnXER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{whUUN3ME2yJO69VS5? NYDYUmUyOTdyOEiwOlc>

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID